<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dasiglucagon: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dasiglucagon: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dasiglucagon: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="131164" href="/d/html/131164.html" rel="external">see "Dasiglucagon: Drug information"</a> and <a class="drug drug_patient" data-topicid="131190" href="/d/html/131190.html" rel="external">see "Dasiglucagon: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F55700929"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Zegalogue</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F55634677"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidote</span>;</li>
<li>
<span class="list-set-name">Antidote, Hypoglycemia</span></li></ul></div>
<div class="block dop drugH1Div" id="F55701043"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6fe33f22-06d5-4e9d-a446-d6156c0d716c">Hypoglycemia, severe; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypoglycemia, severe; treatment: Note: </b>Glucagon products should be prescribed for all patients with type 1 diabetes and patients with type 2 diabetes at increased risk of level 2 (&lt;54 mg/dL) or level 3 hypoglycemia; caregivers, school personnel, and family members of these patients should be trained on when and how to administer glucagon product (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-30093549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-30093549'])">Ref</a></span>). Patients with inadequate glycogen stores (eg, starvation, adrenal insufficiency, chronic hypoglycemia) may not respond to glucagon products and should be treated with glucose.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents: SUBQ: 0.6 mg; if no response after 15 minutes, may give an additional 0.6 mg using a new device.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F55701071"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F55701072"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F55717363"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="131164" href="/d/html/131164.html" rel="external">see "Dasiglucagon: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b7939963-325d-4c86-a77b-b1c6f47494e0">Hypoglycemia, severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypoglycemia, severe:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ: </b>0.6 mg; may repeat in 15 minutes as needed using a new device.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F55717365"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F55717366"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block arsc drugH1Div" id="F56136660"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity reactions, including anaphylaxis, anaphylactic shock, skin rash, erythema multiforme, urticaria, periorbital edema, dizziness, respiratory distress, and <b>hypotension </b>have been reported with administration of glucagon products; no cases specific to dasiglucagon have been identified (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3871290','lexi-content-ref-9051052','lexi-content-ref-2153998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3871290','lexi-content-ref-9051052','lexi-content-ref-2153998'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; immunologic. Glucagon is a protein and has the potential to cause hypersensitivity reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9051052']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9051052'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; within 1 to 2 minutes to 4 hours after administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3871290','lexi-content-ref-9051052','lexi-content-ref-2153998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3871290','lexi-content-ref-9051052','lexi-content-ref-2153998'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F55646495"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. As reported with adults, unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (57%), vomiting (25%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Pain at injection site (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Immunologic: Antibody development</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Cardiovascular: Bradycardia, hypertension, hypotension, orthostatic hypotension, palpitations, presyncope</p></div>
<div class="block coi drugH1Div" id="F55631085"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Pheochromocytoma; insulinoma.</p></div>
<div class="block war drugH1Div" id="F55717353"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Allergic reactions, including skin rash and anaphylactic shock (with hypotension and respiratory difficulties), have been reported.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal insufficiency: Use with caution in patients with adrenal insufficiency; hepatic glycogen levels may be inadequate for dasiglucagon to effectively increase blood glucose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Chronic hypoglycemia: Use with caution in patients with chronic hypoglycemia; hepatic glycogen levels may be inadequate for dasiglucagon to effectively increase blood glucose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Starvation: Use caution with starvation; hepatic glycogen levels may be inadequate for dasiglucagon to effectively increase blood glucose.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F55701042"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Dasiglucagon is only effective if sufficient glycogen stores are present; patients with inadequate storage (eg, starvation, adrenal insufficiency, chronic hypoglycemia) should be treated with glucose.</p></div>
<div class="block foc drugH1Div" id="F55700930"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Subcutaneous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zegalogue: 0.6 mg/0.6 mL (0.6 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Subcutaneous, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zegalogue: 0.6 mg/0.6 mL (0.6 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zegalogue: 0.6 mg/0.6 mL (0.6 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zegalogue: 0.6 mg/0.6 mL (0.6 mL)</p></div>
<div class="block geq drugH1Div" id="F55700928"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F55724848"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (Zegalogue Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.6 mg/0.6 mL (per 0.6 mL): $370.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Zegalogue Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.6 mg/0.6 mL (per 0.6 mL): $370.80</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F55701073"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: SUBQ: For SUBQ use only. Administer SUBQ in the lower abdomen (≥2 inches from belly button), buttocks, thigh, or outer upper arm; do not inject through clothing. Do not reuse the device after administration; a new device should be used for each dose. If patient is unconscious, place patient on side after injecting to prevent choking. Administer fast-acting (eg, fruit juice) and long-acting oral carbohydrates (eg, crackers with cheese or peanut butter) to patient as soon as possible after response to treatment to restore glycogen stores and prevent hypoglycemia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Autoinjector: </i>Remove gray lid and remove autoinjector from protective case, then remove gray cap from needle end of autoinjector. Push the device straight down onto the skin until the needle guard is fully pressed down (may hear click); continue holding the device down against the skin for 10 seconds (until the medicine window is red) before removing to ensure the full dose has been administered.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Prefilled syringe: </i>Remove gray cap and remove prefilled syringe from protective case, then remove gray needle cover.<i></i>Pinch skin and insert entire needle at a 45-degree angle. After inserting needle, release pinched skin and slowly depress plunger until fully depressed and syringe is empty before removing.</p></div>
<div class="block adm drugH1Div" id="F55717368"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> May administer as a SUBQ injection in the outer upper arms, lower abdomen, thighs, or buttocks; do not inject through clothes. If patient is unconscious, place in lateral recumbent position after injecting to prevent choking when consciousness returns. Administer fast-acting and long-acting oral carbohydrates to patient as soon as possible after response to treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Autoinjector: </i>Push the device straight down onto the skin until the needle guard is fully pressed down; hold the needle in the skin for 10 seconds (until the medicine window is red) before removing to ensure the full dose has been administered.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prefilled syringe: </i>Pinch skin and insert needle at a 45-degree angle. After inserting needle, release pinched skin and slowly depress plunger until fully depressed and syringe is empty before removing.</p></div>
<div class="block sts drugH1Div" id="F55717355"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store in protective case refrigerated at 2°C to 8°C (36°F to 46°F) until expiration date, or at room temperature at 20°C to 25°C (68°F to 77°F) for up to 12 months; do not return to refrigeration after storing at room temperature; do not freeze; protect from light.</p></div>
<div class="block usep drugH1Div" id="F55634678"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of severe hypoglycemia in patients with diabetes (FDA approved in ages ≥6 years and adults).</p></div>
<div class="block mst drugH1Div" id="F55717350"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Dasiglucagon may be confused with glucagon.</p>
<p style="text-indent:-2em;margin-left:4em;">Zegalogue may be confused with Zegerid.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F55677966"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F55677963"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indomethacin: May diminish the therapeutic effect of Glucagon and Glucagon Analogs.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Glucagon and Glucagon Analogs may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F55717367"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Administer oral carbohydrates to patient as soon as possible after response to treatment.</p></div>
<div class="block pri drugH1Div" id="F55717351"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were not observed in animal reproduction studies.</p>
<p style="text-indent:0em;margin-top:2em;">Untreated hypoglycemia may lead to adverse pregnancy outcomes. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant patients if there is a clear indication for use and should not be withheld because of concerns of teratogenicity (Bailey 2003).</p></div>
<div class="block mopp drugH1Div" id="F55701101"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood glucose, blood pressure, signs/symptoms of hypersensitivity reactions including anaphylaxis.</p></div>
<div class="block rerp drugH1Div" id="F55701102"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypoglycemia in diabetes</b> (ADA 2021; ISPAD [Abraham 2018]): Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Clinical hypoglycemia alert value </i>(level 1)<i>:</i> 54 to &lt;70 mg/dL (SI: 3 to &lt;3.9 mmol/L); initiate hypoglycemic treatment with fast-acting carbohydrates (ie, glucose tablets, liquid, or gels; ingestion of glucose- or carbohydrate-containing food) to prevent further decrease in plasma glucose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Clinically serious hypoglycemia </i>(level 2): &lt;54 mg/dL (SI: &lt;3 mmol/L); neurogenic symptoms and cognitive dysfunction occur below this concentration; increased risk for severe hypoglycemia; treat with glucagon product.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Severe hypoglycemia </i>(level 3): No specific glucose value; hypoglycemia associated with severe cognitive impairment (including coma and seizures) requiring external assistance for recovery.</p></div>
<div class="block pha drugH1Div" id="F55717356"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Dasiglucagon is a glucagon receptor agonist, which stimulates glycogenolysis and hepatic gluconeogenesis, causing an increase in blood glucose levels; antihypoglycemic effect requires preexisting hepatic glycogen stores.</p></div>
<div class="block phk drugH1Div" id="F55717357"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Median time to plasma glucose recovery: 10 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 47 to 57 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Cleared through proteolytic degradation pathways in blood, liver, and kidney.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~30 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Pediatric patients: 7 to 17 years of age: ~21 minutes; Adults: ~35 minutes.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58216505"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Zegalogue</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-29869358">
<a name="29869358"></a>Abraham MB, Jones TW, Naranjo D, et al. ISPAD clinical practice consensus guidelines 2018: Assessment and management of hypoglycemia in children and adolescents with diabetes. <i>Pediatr Diabetes</i>. 2018;19 Suppl 27:178-192.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasiglucagon-pediatric-drug-information/abstract-text/29869358/pubmed" id="29869358" target="_blank">29869358</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2021">
<a name="ADA.2021"></a>American Diabetes Association (ADA). Standards of medical care in diabetes–2021.<i> Diabetes Care.</i> 2021;44(suppl 1):S1-S232. https://care.diabetesjournals.org/content/44/Supplement_1. Accessed April 9, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2">
<a name="ADA.2"></a>American Diabetes Association (ADA). Standards of care in diabetes–2023. <i>Diabetes Care</i>. 2023;46(suppl 1):S1-S291. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed January 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12769509">
<a name="12769509"></a>Bailey B. Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women? <i>Birth Defects Res A Clin Mol Teratol</i>. 2003;67(2):133-140. doi:10.1002/bdra.10007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasiglucagon-pediatric-drug-information/abstract-text/12769509/pubmed" id="12769509" target="_blank">12769509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30093549">
<a name="30093549"></a>Chiang JL, Maahs DM, Garvey KC, et al. Type 1 diabetes in children and adolescents: a position statement by the American Diabetes Association. <i>Diabetes Care</i>. 2018;41(9):2026-2044.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasiglucagon-pediatric-drug-information/abstract-text/30093549/pubmed" id="30093549" target="_blank">30093549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3871290">
<a name="3871290"></a>Gelfand DW, Sowers JC, DePonte KA, Sumner TE, Ott DJ. Anaphylactic and allergic reactions during double-contrast studies: is glucagon or barium suspension the allergen?. <i>AJR Am J Roentgenol</i>. 1985;144(2):405-406. doi:10.2214/ajr.144.2.405<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasiglucagon-pediatric-drug-information/abstract-text/3871290/pubmed" id="3871290" target="_blank">3871290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9051052">
<a name="9051052"></a>Herskovitz PI, Sendovski U. Severe allergic reaction to intravenous injection of glucagon. <i>Radiology</i>. 1997;202(3):879. doi:10.1148/radiology.202.3.9051052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasiglucagon-pediatric-drug-information/abstract-text/9051052/pubmed" id="9051052" target="_blank">9051052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2153998">
<a name="2153998"></a>Zavras GM, Papadaki PJ, Kounis NG, Dimopoulos JA. Glucagon-induced severe anaphylactic reaction. <i>Rofo</i>. 1990;152(1):110. doi:10.1055/s-2008-1046831<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasiglucagon-pediatric-drug-information/abstract-text/2153998/pubmed" id="2153998" target="_blank">2153998</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Zegalogue (dasiglucagon) [prescribing information]. Søborg, Denmark: Zealand Pharma A/S; April 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 131165 Version 42.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
